Navigation Links
Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
Date:8/19/2007

- Planning for Phase 3 Trial Initiation on Track -

BRISBANE, Australia, Aug. 16 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced it has executed an agreement with Quintiles, the world's largest Contract Research Organisation, to utilise their services for a number of clinical development- related projects. This agreement includes the execution of the Phase 3 clinical trial of anti-cancer drug PI-88 for the treatment of primary liver cancer (hepatocellular carcinoma).

Progen remains on track to initiate recruitment for the Phase 3 clinical trial in the fourth quarter of 2007. Quintiles operates directly in each of the 14 North American, European and Asian countries where Progen will be conducting the Phase 3 PI-88 trial.

"Quintiles has over 18,000 employees world-wide and has managed over 520 separate oncology studies. A number of these employees have been working with us as we prepare to initiate our Phase 3 trial in post-resection liver cancer. We have been consistently impressed with Quintiles's infrastructure in the regions where the trial will be conducted. They have already demonstrated to us that they have the communication and project management systems in place to successfully integrate key clinical operational procedures on the international level that this important trial requires," said Justus Homburg, Progen's CEO.

"Since the middle of last year, we have been working with external advisors, including Quintiles and the U.S. Food and Drug Administration (FDA), to develop our Phase 3 trial. We are aggressively pursuing the launch of this clinical trial on schedule and in parallel continue our discussions with the FDA on the SPA process," concluded Mr. Homburg.

The primary endpoint of the Phase 3 trial is the length of time patients remain disease-free (disease free survival or DFS) following surgery to remove tumour-affected parts of the liver. "Recent feedback f
'/>"/>

SOURCE Progen Pharmaceuticals Limited

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets has ... Therapeutics Market & Pipeline Insight 2014" report to ... to prevent and eradicate the prevalence of cancer have ... confined to low specificity, safety and large number of ... a better solution. It has been discovered that peptides ...
(Date:8/29/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... District of New Jersey has ... Sandoz, Inc. regarding United Therapeutics, Remodulin ® product.  In ... U.S. Patent No. 6,765,117 is both valid and enforceable ... generic product until the expiration of that patent in ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... Barcelona, Spain Saturday 30 August 2014: Transvenous lead ... of cases according to data from the European Lead ... today at ESC Congress 2014 by Dr Maria Grazia ... Bongiorni said: "The number of cardiac implantable electronic devices ... advances in technology the number of complications has increased ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Top10BestSEOHosting.com ... experienced researchers have announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... the current market. Also, they has announced that ... webmasters. , Hostgator, one of the Top ... supplier of cheap Windows hosting, and it offers ...
(Date:8/30/2014)... Tulsa, OK (PRWEB) August 30, 2014 LiveStreamingFitness.com, ... as well as other healthy lifestyle resources, is proud to ... affordable nationwide resources for at home fitness solutions by ABC’s ... a recent featured story on ABC’s Good Morning America, “Live ... Now, you can streamline your day by streamlining your workout…to ...
(Date:8/30/2014)... McLeod's Sunset Park Auto Service , ... with strong ties to the community celebrates sixty years in ... they have been chosen by The Tampa Tribune’s ... , Tim McLeod’s father, Norris (most know him as ... Although his son, Tim runs the day to day, taking ...
(Date:8/30/2014)... August 30, 2014 Zensah®, the leader in ... Compression Leg Sleeve . The camo sleeves are the first ... collection. The camo line includes classic colors like army ... , Known as tibial stress syndrome, shin splints cause ... lower leg. Swollen and irritated muscles, stress fractures, or over ...
Breaking Medicine News(10 mins):Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2
... culture play a role, expert contends, , WEDNESDAY, Sept. 30 ... complications of surgery, not just the rate of those complications, ... found. , The study, which included more than 84,000 people ... twofold difference in surgical deaths between hospitals with the lowest ...
... children don,t see their family dentist until they are well ... both dental and medical professionals. , That,s one of the ... conducted on behalf of Delta Dental Plans Association, the nation,s ... gain greater knowledge about the state of children,s oral health. ...
... The Sleep Center at Baylor University Medical Center at ... Sleep Medicine. The center at Baylor Dallas is one ... , "Accreditation provides formal recognition of our commitment ... from sleep disorders," said David L. Luterman, M.D., sleep ...
... by Weill Cornell Medical College researchers looks at the ... drink and use marijuana in combination. Among their findings: ... (smoking, drinking and marijuana), and that this manifested itself ... were shown to be central. Ambivalent or permissive attitudes ...
... The Drug ... and Risks of Medicinal Products in Regulatory Decisions from November 3- 5, 2009 in Bethesda, ... Horsham, PA (Vocus) ... and Drug Administration (USFDA) will host Assessing Benefits and Risks of Medicinal Products in ...
... ... is inviting all tailgating aficionados to grab a video camera and show the world their ... , ... 2009 -- http://www2.samsclub.com/tailgatechallenge , , , , ,It,s Simple - Upload to win ,With ...
Cached Medicine News:Health News:Surgical Deaths Linked to Handling of Complications 2Health News:Surgical Deaths Linked to Handling of Complications 3Health News:Delayed First Visit to Dentist Can Affect Children's Lifelong Oral Health 2Health News:Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 2Health News:Teen attitudes toward smoking linked to likelihood of drinking and using drugs 2Health News:Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 2Health News:Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 3Health News:Sam's Club Tailgate Challenge Video Contest: Show Sam's Club Your Best Tailgating Style for a Chance To Win a $1,000 Gift Card 2Health News:Sam's Club Tailgate Challenge Video Contest: Show Sam's Club Your Best Tailgating Style for a Chance To Win a $1,000 Gift Card 3
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Medicine Products: